Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Evommune, Inc.NYSE: EVMN
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow grows to $0
Q1 FY2026 stock-based compensation was $0, compared with $0 a year earlier. Trailing-twelve-month stock-based compensation was $0.
Context
- Stock-based compensation amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Stock-based compensation increased in 0 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
Stock-Based Compensation vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's LTM Mar 2026 stock-based compensation of $0 is the smallest of the 10 companies compared; the peer median is $15.02M.
- Stock-based compensation amounts to 0.0% of revenue for EVMN, versus a peer median of 14.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
FTREFortrea Holdings Inc. | LTM Jun 2026 | $61.1M | +21.5% | +43.1% | 2.3% |
| LTM Jun 2026 | $53.27M | +57.8% | — | 18.3% | |
| LTM Sep 2026 | $37.94M | +56.7% | +91.1% | 14.3% | |
| LTM Mar 2026 | $31.69M | -0.5% | +25.3% | 416.2% | |
| LTM Mar 2026 | $15.02M | -24.7% | -4.8% | 52.0% | |
| LTM Mar 2026 | $13.5M | -20.7% | -26.5% | 8.9% | |
| LTM Mar 2026 | $8.67M | -29.5% | -12.8% | 11.1% | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $7.64M | +7.4% | +4.8% | — |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $6.36M | -16.6% | +1.2% | — |
EVMNEvommune, Inc. | LTM Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding EVMN) | $15.02M | -0.5% | +3.0% | 14.3% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (34.05M) | (66.81M) | (68.87M) |
| Depreciation & Amortization | 1M | 1.29M | 1.39M |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 |
| Change in Working Capital | 3.34M | 7.42M | (4.12M) |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | 125K | 6.51M | (837K) |
| Other Working Capital | 3.22M | 918K | (3.28M) |
| Other Non-Cash Items | (261K) | (98K) | (4.84M) |
| Operating Cash Flow | (29.97M) | (58.2M) | (76.44M) |
| Capital Expenditures | (118K) | (88K) | (235K) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | (91.31M) | (90.26M) | (199.17M) |
| Sales of Investments | 43M | 86.35M | 84.1M |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | (48.43M) | (3.99M) | (115.31M) |
| Debt Repayment | 0 | 0 | (373K) |
| Common Stock Issued | 63.98M | 49.84M | 222.36M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | (230K) | (423K) | (1.22M) |
| Financing Cash Flow | 63.75M | 49.42M | 220.76M |
| Effect of Forex Changes | 43.67M | (1) | (1.21M) |
| Net Change in Cash | 29.02M | (12.77M) | 27.81M |
| Free Cash Flow | (30.09M) | (58.28M) | (76.68M) |
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.